AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G/A] Phio Pharmaceuticals Corp. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: All ownership percentages set forth in this Schedule 13G are calculated based upon an aggregate of 5,726,750 shares of Common Stock outstanding after giving effect to the completion of the Issuer's warrant inducement transaction and excludes 947,954 shares of Common Stock issuable upon the exercise of warrants, subject to the 4.99% blocker (defined below). Pursuant to the terms of the warrants, the Reporting Person cannot exercise any of the warrants to the extent the Reporting Person would beneficially own, after any such exercise, more than 4.99% of the Issuer's outstanding Common Stock (the "4.99% Blocker").


SCHEDULE 13G



Orca Capital AG
Signature:/s/ Thomas Konig
Name/Title:Thomas Konig/Director
Date:08/07/2025
Phio Pharmaceuticals Corp

NASDAQ:PHIO

PHIO Rankings

PHIO Latest News

PHIO Latest SEC Filings

PHIO Stock Data

10.27M
4.74M
1.14%
15.77%
6.86%
Biotechnology
Pharmaceutical Preparations
United States
MARLBOROUGH